This report was recently updated on April 13 2024 with the latest and most recent
market numbers
Global Neuroendocrine Carcinoma Market Size, Trends, and Analysis - Forecasts To 2026 By Site (Gastrointestinal, Lung, Brain, Pancreas, and Others), By Therapy (Surgery, Radiation Therapy, and Chemotherapy), By Diagnostic Tools (Imaging, Biopsy, Serology, and Others), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
A neuroendocrine tumor is cancer that starts in the hormone-producing cells of the neuroendocrine system, which includes the nervous and endocrine systems. Hormone-producing neuroendocrine cells resemble neurons in structure and release hormones in the same way as endocrine cells do. These cells can be located in organs such as the kidneys, intestines, stomach, and lungs, and carry out activities such as regulating the speed at which food passes via the gastrointestinal system and oxygen and blood circulation via the lungs. Neuroendocrine tumors are a relatively uncommon malignancy that accounts for less than 1% of all tumors. Neuroendocrine carcinomas are neuroendocrine tumors that originate in various parts of the body, such as the brain, gastrointestinal system, and lungs. They accounted for about 60% of all neuroendocrine tumor instances.
Owing to a rise in the prevalence of neuroendocrine tumors (NETs) all over the world, the global neuroendocrine carcinoma market is projected to expand significantly over the estimated timeframe. This form of cancer develops in the human body's neuroendocrine system and releases hormones that are close to those produced by neuroendocrine cells. Increased research & development investments for the advancement of cost-efficient next-generation sequencing methods used to create novel cancer therapeutic strategies, as well as ongoing clinical trials, are anticipated to propel the neuroendocrine carcinoma market further. Over the forecast timeline, increased awareness is projected to boost business expansion. For example, many organizations around the globe are launching campaigns nationally and internationally to raise awareness of neuroendocrine tumors and encourage early detection. Each year on November 10, for example, the International Neuroendocrine Cancer Alliance commemorates the neuroendocrine day. Sellers will also benefit from such awareness campaigns by further understanding business prospects and investing in research to produce innovative therapies.
The increased cost of production and the occurrence of adverse effects of the drugs for neuroendocrine carcinoma is likely to stifle the market. Gallstone formation, high blood glucose, and mild digestive system upset, like nausea and bloating, are all potential side effects.
The market can be divided into the lung, gastrointestinal, pancreas, brain, and other segments based on site. Due to the rising incidence of gastrointestinal NET amongst individuals all over the world, the gastrointestinal NET category is projected to rise at the fastest pace over the estimated timeframe. GI problems can occur due to the ill habits of eating junk and non-nutritional food items. GI-NETs are uncommon, but their frequency and proliferation are on the rise. Their histopathology, genetics, and clinical behavior are all distinct. They are usually slow-growing tumors, but based on the area, scale, and grading of the tumor, they can develop quickly at times. Lung Neuroendocrine Carcinomas are also anticipated to grow at the fastest rate. The single most important potential cause for developing small cell lung carcinoma is smoking. Exposure to asbestos and radon are two other possible causes.
Chemotherapy, radiation therapy, and surgery are part of the therapy segment. Radiofrequency ablation (RFA) and local excision are two different types of surgery. The only therapeutic approach for pancreatic NETs is radiofrequency ablation and hence it is anticipated to see significant development. However, risks associated with the procedure, such as tumor growth, pancreatic fistula, and bleeding, are likely to delay adoption in the near future. Renal tumors are typically treated with local excision.
Chemotherapy is an effective therapy choice for pancreatic NETs, but no reliable therapy alternative for carcinoid tumors has yet been discovered. In the cases of slow-growing cancers, surgical excision coupled with chemotherapy is often used.
The market has been categorized into biopsy, imaging, serology, and others based on diagnostic tools. The serology segment is further segmented into blood tests, urine tests, molecular tests, and others. The imaging section is divided into PET scan, X-ray, CT scan, and other types of imaging. The imaging category is expected to expand due to the growing acceptance of specialized diagnostic imaging technologies that can diagnose very small, clinically negligible malignant tumors. Neuroendocrine tumors are a rare malignancy that can be assessed in a range of forms using imaging. CT, OctreoScan, and MRI are ideal preliminary trials for locating the primary tumor, evaluating the seriousness of the disorder, and planning surgical intervention.
North America is expected to hold the largest share of the neuroendocrine carcinoma market. Because of the rising prevalence of NETs in the United States, this region has become the main target for investment and new product development. Owing to the prevalence of a significant patient community in this country, the United States ranks first in the amount of NET clinical studies worldwide, followed by the United Kingdom.
The Asia Pacific neuroendocrine carcinoma market is expected to expand rapidly owing to a rise in the prevalence of NETs and the region's strengthening state of the economy. Owing to a strong patient base, expanding health care facilities, and growing government spending in healthcare services in the area, the Asia Pacific neuroendocrine carcinoma market is projected to expand exponentially during the projected timeline. Furthermore, the neuroendocrine carcinoma market is expected to expand due to the rising prevalence of cancer cases across the APAC region.
Some of the key participants operating in the neuroendocrine carcinoma market are Amgen Inc., Exelixis, Inc., Jubilant Life Sciences Ltd, Novartis AG, Hutchison MediPharma Limited, Delcath Systems Inc., Aegis Therapeutics, AVEO Pharmaceuticals, Inc., Ispen, Pfizer, Dauntless Pharmaceuticals, Progenics Pharmaceuticals, Inc., AbbVie Inc., Tarveda Therapeutics, Chiasma Inc., Boehringer Ingelheim GmbH, and others.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview and Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Neuroendocrine Carcinoma Industry Overview, 2019-2026
2.1.1 Industry Overview
2.1.2 Site Overview
2.1.3 Therapy Overview
2.1.4 Diagnostic Tool Overview
2.1.6 Regional Overview
Chapter 3 Neuroendocrine Carcinoma Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2019-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Diagnostic Tool Advancement in Neuroendocrine Carcinoma Test
3.3.1.2 Rising Prevalence of Cancer Cases
3.3.2 Industry Challenges
3.3.2.1 Lack of Adequate Infrastructure and Automated Laboratory Systems in Developing Nations
3.4 Prospective Growth Scenario
3.4.1 Site Growth Scenario
3.4.2 Therapy Growth Scenario
3.4.3 Diagnostic Tool Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Diagnostic Tool Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Neuroendocrine Carcinoma Market, By Site
4.1 Site Outlook
4.2 Gastrointestinal
4.2.1 Market Size, By Region, 2019-2026 (USD Million)
4.3 Lung
4.3.1 Market Size, By Region, 2019-2026 (USD Million)
4.4 Brain
4.4.1 Market Size, By Region, 2019-2026 (USD Million)
4.5 Pancreas
4.5.1 Market Size, By Region, 2019-2026 (USD Million)
4.6 Others
4.6.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 5 Neuroendocrine Carcinoma Market, By Therapy
5.1 Therapy Outlook
5.2 Surgery
5.2.1 Market Size, By Region, 2019-2026 (USD Million)
5.3 Radiation Therapy
5.3.1 Market Size, By Region, 2019-2026 (USD Million)
5.4 Chemotherapy
5.4.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 6 Neuroendocrine Carcinoma Market, By Diagnostic Tool
6.1 Imaging
6.1.1 Market Size, By Region, 2019-2026 (USD Million)
6.2 Biopsy
6.2.1 Market Size, By Region, 2019-2026 (USD Million)
6.3 Serology
6.3.1 Market Size, By Region, 2019-2026 (USD Million)
6.4 Others
6.4.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 8 Neuroendocrine Carcinoma Market, By Region
8.1 Regional outlook
8.2 North America
8.2.1 Market Size, By Country 2019-2026 (USD Million)
8.2.2 Market Size, By Site, 2019-2026 (USD Million)
8.2.3 Market Size, By Therapy, 2019-2026 (USD Million)
8.2.4 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.2.6 U.S.
8.2.6.1 Market Size, By Site, 2019-2026 (USD Million)
8.2.4.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.2.4.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.2.7 Canada
8.2.7.1 Market Size, By Site, 2019-2026 (USD Million)
8.2.7.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.2.7.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.3 Europe
8.3.1 Market Size, By Country 2019-2026 (USD Million)
8.3.2 Market Size, By Site, 2019-2026 (USD Million)
8.3.3 Market Size, By Therapy, 2019-2026 (USD Million)
8.3.4 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.3.6 Germany
8.3.6.1 Market Size, By Site, 2019-2026 (USD Million)
8.3.6.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.3.6.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.3.7 UK
8.3.7.1 Market Size, By Site, 2019-2026 (USD Million)
8.3.7.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.3.7.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.3.8 France
8.3.8.1 Market Size, By Site, 2019-2026 (USD Million)
8.3.8.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.3.8.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.3.9 Italy
8.3.9.1 Market Size, By Site, 2019-2026 (USD Million)
8.3.9.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.3.9.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.3.10 Spain
8.3.10.1 Market Size, By Site, 2019-2026 (USD Million)
8.3.10.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.3.10.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.3.11 Russia
8.3.11.1 Market Size, By Site, 2019-2026 (USD Million)
8.3.11.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.3.11.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.4 Asia Pacific
8.4.1 Market Size, By Country 2019-2026 (USD Million)
8.4.2 Market Size, By Site, 2019-2026 (USD Million)
8.4.3 Market Size, By Therapy, 2019-2026 (USD Million)
8.4.4 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.4.6 China
8.4.6.1 Market Size, By Site, 2019-2026 (USD Million)
8.4.6.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.4.6.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.4.7 India
8.4.7.1 Market Size, By Site, 2019-2026 (USD Million)
8.4.7.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.4.7.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.4.8 Japan
8.4.8.1 Market Size, By Site, 2019-2026 (USD Million)
8.4.8.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.4.8.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.4.9 Australia
8.4.9.1 Market Size, By Site, 2019-2026 (USD Million)
8.4.9.2 Market size, By Therapy, 2019-2026 (USD Million)
8.4.9.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.4.10 South Korea
8.4.10.1 Market Size, By Site, 2019-2026 (USD Million)
8.4.10.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.4.10.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.5 Latin America
8.5.1 Market Size, By Country 2019-2026 (USD Million)
8.5.2 Market Size, By Site, 2019-2026 (USD Million)
8.5.3 Market Size, By Therapy, 2019-2026 (USD Million)
8.5.4 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.5.6 Brazil
8.5.6.1 Market Size, By Site, 2019-2026 (USD Million)
8.5.6.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.5.6.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.5.7 Mexico
8.5.7.1 Market Size, By Site, 2019-2026 (USD Million)
8.5.7.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.5.7.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.5.8 Argentina
8.5.8.1 Market Size, By Site, 2019-2026 (USD Million)
8.5.8.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.5.8.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.6 MEA
8.6.1 Market Size, By Country 2019-2026 (USD Million)
8.6.2 Market Size, By Site, 2019-2026 (USD Million)
8.6.3 Market Size, By Therapy, 2019-2026 (USD Million)
8.6.4 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.6.6 Saudi Arabia
8.6.6.1 Market Size, By Site, 2019-2026 (USD Million)
8.6.6.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.6.6.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.6.7 UAE
8.6.7.1 Market Size, By Site, 2019-2026 (USD Million)
8.6.7.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.6.7.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
8.6.8 South Africa
8.6.8.1 Market Size, By Site, 2019-2026 (USD Million)
8.6.8.2 Market Size, By Therapy, 2019-2026 (USD Million)
8.6.8.3 Market Size, By Diagnostic Tool, 2019-2026 (USD Million)
Chapter 9 Company Landscape
9.1 Competitive Analysis, 2020
9.2 Amgen
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Strategic Positioning
9.2.4 Info Graphic Analysis
9.3 Exelixis, Inc
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Strategic Positioning
9.3.4 Info Graphic Analysis
9.4 Jubilant Life Sciences Ltd
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Strategic Positioning
9.4.4 Info Graphic Analysis
9.5 Novartis AG
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Strategic Positioning
9.5.4 Info Graphic Analysis
9.6 Hutchison MediPharma Limited
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Strategic Positioning
9.6.4 Info Graphic Analysis
9.7 Delcath Systems Inc
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Strategic Positioning
9.7.4 Info Graphic Analysis
9.8 Aegis Therapeutics
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Strategic Positioning
9.8.4 Info Graphic Analysis
9.9 AVEO Pharmaceuticals, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Strategic Positioning
9.9.4 Info Graphic Analysis
9.10 Ispen
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Strategic Positioning
9.10.4 Info Graphic Analysis
9.11 Other Companies
9.11.1 Company Overview
9.11.2 Financial Analysis
9.11.3 Strategic Positioning
9.11.4 Info Graphic Analysis
The Global Neuroendocrine Carcinoma Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Neuroendocrine Carcinoma Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
